GlassScriptPhysician profile
Jayanti Venkatesan
NPI 1932158128
$2,542.11
in general payments reported to CMS, 2019-2025
29 companies · $443 in 2025
The $443 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $691 · 2020: $733 · 2021: $35.39 · 2022: $164 · 2023: $234 · 2024: $241 · 2025: $443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $919.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $425.38 | 2019-2025 | Farxiga |
| Akebia Therapeutics INC | $288.47 | 2019-2025 | Vafseo |
| Vifor Pharma, INC. | $261.39 | 2019-2023 | Veltassa |
| Fresenius USA Marketing, INC. | $230.84 | 2019-2023 | Korsuva, Velphoro |
| Mallinckrodt Hospital Products INC. | $157.28 | 2020-2024 | Terlivaz |
| Horizon Therapeutics Plc | $144.14 | 2019-2023 | Krystexxa |
| Amgen INC. | $125.13 | 2019-2024 | Krystexxa |
| Opko Pharmaceuticals, LLC | $112.43 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $84.28 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $77.21 | 2023-2025 | Lupkynis |
| Recordati_rare_diseases_inc. | $68.07 | 2024-2025 | Isturisa, Signifor Lar |
| Genentech USA, INC. | $52.66 | 2019 | |
| Lilly USA, LLC | $51.92 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $51.29 | 2025 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $47.29 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $46.88 | 2025 | |
| Corcept Therapeutics | $41.66 | 2024 | Korlym |
| Glaxosmithkline, LLC. | $41.08 | 2023 | Benlysta |
| Otsuka America Pharmaceutical, INC. | $30.29 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $27.22 | 2025 | Purified Cortrophin Gel |
| Mallinckrodt Enterprises LLC | $25.72 | 2019 | |
| Madrigal Pharmaceuticals | $24.68 | 2025 | Rezdiffra |
| Alexion Pharmaceuticals, INC. | $23.47 | 2019 | |
| Genzyme Corporation | $22.76 | 2019 | |
| Shire North American Group INC | $20.30 | 2019 | |
| Acella Pharmaceuticals, LLC | $17.83 | 2025 | NP Thyroid 60 |
| Travere Therapeutics, INC. | $15.57 | 2024 | |
| Mannkind Corporation | $15.27 | 2025 | |
| Beta Bionics, INC. | $11.60 | 2024 | Ilet Bionic Pancreas |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayanti Venkatesan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.